Document Detail

Asparaginase-associated myelosuppression and effects on dosing of other chemotherapeutic agents in childhood acute lymphoblastic leukemia.
MedLine Citation:
PMID:  22532399     Owner:  NLM     Status:  MEDLINE    
Although L-asparaginase (ASP) is associated with several toxicities, its myelosuppressive effect has not been well characterized. On DFCI ALL Consortium Protocol 05-01 for children with newly diagnosed acute lymphoblastic leukemia, the Consolidation phase and the initial portion of the Continuation phase were identical for standard risk patients, except ASP was given only during Consolidation. Comparing the two treatment phases revealed that low blood counts during Consolidation with ASP resulted in more dosage reductions of 6-mercaptopurine and methotrexate. The myelosuppressive effect of ASP should be considered when designing treatment regimens to avoid excessive toxicity and dose reductions of other critical chemotherapy agents.
Reid Merryman; Kristen E Stevenson; William J Gostic; Donna Neuberg; Jane O'Brien; Stephen E Sallan; Lewis B Silverman
Related Documents :
15139069 - Time dependence of prognostic factors for patients with soft tissue sarcoma: a scandina...
22702479 - Long-term radiosurgical control of subtotally resected adult pineocytomas.
22298979 - Prognostic value of liver fibrosis biomarkers: a meta-analysis.
22298089 - Proton pump inhibitor use and recurrent clostridium difficile-associated disease: a cas...
22443079 - Clinical outcome of amrubicin therapy according to the prior chemotherapy sensitivities...
22634799 - Bevacizumab plus irinotecan in recurrent malignant glioma shows high overall survival i...
1347979 - Successful autograft with peripheral blood stem cells in a child with t-lymphoblastic l...
19373949 - Limb-sparing in patients with non-metastatic high-grade osteosarcoma.
1879089 - Dermatomyositis associated with the recurrence of transitional cell carcinomas and kapo...
Publication Detail:
Type:  Clinical Trial; Comparative Study; Journal Article; Multicenter Study     Date:  2012-04-24
Journal Detail:
Title:  Pediatric blood & cancer     Volume:  59     ISSN:  1545-5017     ISO Abbreviation:  Pediatr Blood Cancer     Publication Date:  2012 Nov 
Date Detail:
Created Date:  2012-09-13     Completed Date:  2012-11-30     Revised Date:  2013-06-21    
Medline Journal Info:
Nlm Unique ID:  101186624     Medline TA:  Pediatr Blood Cancer     Country:  United States    
Other Details:
Languages:  eng     Pagination:  925-7     Citation Subset:  IM    
Copyright Information:
Copyright © 2012 Wiley Periodicals, Inc.
Harvard Medical School, Boston, Massachusetts, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
6-Mercaptopurine / administration & dosage,  adverse effects
Antineoplastic Combined Chemotherapy Protocols / administration & dosage*,  adverse effects
Asparaginase / administration & dosage*,  adverse effects
Child, Preschool
Methotrexate / administration & dosage,  adverse effects
Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy*
Grant Support
Reg. No./Substance:
50-44-2/6-Mercaptopurine; 59-05-2/Methotrexate; EC

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Iridium-Catalyzed Enantioselective Hydrogenation of Alkenylboronic Esters.
Next Document:  Prediction of successful labor induction using transvaginal sonographic cervical measurements.